A Phase II Trial of Flavopiridol (NSC 649890) Administered as a 72-Hour Continuous Infusion Every 2 Weeks in Patients With Previously Treated Intermediate and High Grade Non-Hodgkin's Lymphoma Including Mantle Cell Lymphoma
I. Determine the objective response rate to flavopiridol by patients with previously treated
intermediate and high grade non-Hodgkin's lymphoma and mantle cell lymphoma.
II. Determine the toxicity of flavopiridol administered as a continuous infusion every 2
weeks in these patients.
III. Study the pharmacokinetics of flavopiridol in these patients.
OUTLINE: This is an open label, multi-institutional study.
Patients receive treatment on an outpatient basis. Flavopiridol is administered as a
continuous infusion over 72 hours every 2 weeks. Patients receive a minimum of 4 cycles of
therapy unless unacceptable toxicity or disease progression occurs. Patients are followed
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Todd M. Zimmerman, MD
University of Chicago
United States: Food and Drug Administration
|University of Chicago Cancer Research Center||Chicago, Illinois 60637|
|Evanston Northwestern Health Care||Evanston, Illinois 60201|
|Lutheran General Hospital||Park Ridge, Illinois 60068|
|Louis A. Weiss Memorial Hospital||Chicago, Illinois 60640|
|Clinical Sciences Building||Chicago, Illinois 60612|
|Cancer Care Specialists of Central Illinois, S.C.||Decatur, Illinois 62526|
|Oncology/Hematology Associates of Central Illinois, P.C.||Peoria, Illinois 61602|
|Central Illinois Hematology Oncology Center||Springfield, Illinois 62701|
|Fort Wayne Medical Oncology and Hematology, Inc.||Fort Wayne, Indiana 46885-5099|
|Michiana Hematology/Oncology P.C.||South Bend, Indiana 46617|